PLAY PODCASTS
Chasing Lifesaving Cures for Himself and Others - Dr. David Fajgenbaum, President of the Castleman Disease Collaborative Network
Episode 309

Chasing Lifesaving Cures for Himself and Others - Dr. David Fajgenbaum, President of the Castleman Disease Collaborative Network

“I knew I wasn't going to survive unless I found a drug that could save my life,” says Dr. David Fajgenbaum, who has almost died five times from the rare disorder idiopathic multicentric Castleman disease, which he developed while in medical school. Now a physician and assistant professor at the University of Pennsylvania, Fajgenbaum has led research efforts into a cure for Castleman, discovering a drug that has kept him disease-free for eight years and is helping other patients. As he continues pursuing new therapies for Castleman, Fajgenbaum is also spearheading an effort to create a system for identifying alternate uses for existing drugs, something which could benefit millions in the rare disease community and beyond. “One of my favorite examples is tocilizumab, which was made for Castleman in the 1990’s and is now the first drug you'll receive if you're admitted to the ICU with COVID,” he tells host Shiv Gaglani. The non-profit effort is being announced this month at a Clinton Global Initiative meeting. Don’t miss this deeply inspiring conversation with many lessons on the importance of collaboration, laughter and hope, and the perspective gained from feeling like you are living on borrowed time. Mentioned in this episode: www.chasingmycure.com

Raise the Line · Dr. David Fajgenbaum, Shiv Gaglani

August 31, 202226m 46s

Audio is streamed directly from the publisher (cdn.simplecast.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.

Show Notes

“I knew I wasn't going to survive unless I found a drug that could save my life,” says Dr. David Fajgenbaum, who has almost died five times from the rare disorder idiopathic multicentric Castleman disease, which he developed while in medical school. Now a physician and assistant professor at the University of Pennsylvania, Fajgenbaum has led research efforts into a cure for Castleman, discovering a drug that has kept him disease-free for eight years and is helping other patients. As he continues pursuing new therapies for Castleman, Fajgenbaum is also spearheading an effort to create a system for identifying alternate uses for existing drugs, something which could benefit millions in the rare disease community and beyond. “One of my favorite examples is tocilizumab, which was made for Castleman in the 1990’s and is now the first drug you'll receive if you're admitted to the ICU with COVID,” he tells host Shiv Gaglani.

The non-profit effort is being announced this month at a Clinton Global Initiative meeting. Don’t miss this deeply inspiring conversation with many lessons on the importance of collaboration, laughter and hope, and the perspective gained from feeling like you are living on borrowed time.  

Mentioned in this episode: www.chasingmycure.com

If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Topics

continuing educationomicrondoctorsmedical degreescoronavirusfrontline providerspfizerraise the linevirusinterviewnursing schoolflatten the curveelseviernursing cmenurseshealthcare capacityastra zenecacovid-19rare disordershealthcare workforceexpertsmedical educationlearning sciencenursing educationsolutionsrishi desaiepidemicosmosisdelta variantuniversity of pennsylvaniahealthcare systemosmosis.orgdavid fajgenbaumrare diseasesvirus outbreakjannah amielonline educationcovid19shiv gaglanicastleman diseasemodernapodcastsnursing degreepublic healthvaccinestestingchasing my curehealth professionspandemicjohnson & johnson